What We’re Reading, July 15, 2016: What can the 7 remaining co-ops do to survive; CMS projects increased Medicare spending per enrollee by 2025; and experts call for policy changes to support the health of prisoners at high risk for HIV.
With the rapid failure of the health insurance co-ops—with 4 more announcing there are shutting doors in just the past 2 weeks—only 7 of the initial 23 will still be operational when enrollment begins in fall of this year. Survival will be the bottom line for the remaining consumer operated and oriented plans, as they are called under the Affordable Care Act, since all of them posted losses in 2015, according to Kaiser Health News. According to Timothy Jost, a law professor at Washington and Lee University in Virginia, co-ops are an important alternative to commercial insurers.
According to the CMS Office of the Actuary, the government will be spending over $10,000 a person. The study, which was published in Health Affairs, says healthcare spending will be 20% of the economy by 2025. With 1 in 5 Americans on Medicare, CMS will spend nearly $18,000 annually per member. The lead author on the study, Sean P. Keehan, an economist at the actuary’s office at CMS, told The New York Times that a significant amount of this spending would be the result of high drug prices and greater use of specialty medications.
A series of articles published in The Lancet by experts from the infectious disease field are appealing for policy changes to improve access to treatment, prevention, and care of prisoners post release—especially for those prisoners who are at a high risk of HIV infections. The articles propose solutions such as harm-reduction and drug treatment programs to reduce disease transmission.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen